Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
37 results
D2.02 - Clinically Relevant Cross-Reactivity Between Artemisia vulgaris and Bee Pollen: A New Paradigm in Postprandial Exercise-Induced Anaphylaxis
D2.04 - PREVALENCE OF ALPHA-GAL SENSITIZATION IN PATIENTS WITH ARTHROPOD BITE REACTIONS, CHRONIC SPONTANEOUS URTICARIA AND GASTROINTESTINAL SYMPTOMS IN LA RIOJA (SPAIN). Introduction
D2.06 - Clinical Characteristics of Reactions to Oral Food Challenges with Egg- and Milk-Based Muffins in Children
D2.07 - Cross-reactivity of Major Pollen Allergens in Spring in Beijing
D2.08 - Extraction Efficiency Studies and Quantification of Major Peanut Allergens in Peanut Challenge Meals and Peanut Flour
D2.09 - Qualitative concordance between two multiplex molecular diagnostic platforms in LTP allergy
D2.10 - Early-onset cow’s milk protein and tree nut allergy: the value of component-resolved diagnosis in interpreting low-level alpha-gal sensitization
D2.12 - Resolving heterophile antibody interference in the ISAC multiplex assay using HBT (Scantibodies)
D2.13 - Migratory locust and house cricket as food allergy: cross reactivity or primary sensitivisation
D2.14 - Component ratio analysis supports a targeted diagnostic approach in house dust mite allergy
D2.03 - Cofactor-Dependent Anaphylaxis to Rosaceae and Citrus Fruits: Molecular Characterization Reveals High-Molecular-Weight Allergens Beyond Classical Panallergens
D2.05 - Quail Egg Allergy with Independent Hen Egg Sensitization: Insights From Protein Profiling and Inhibition Assays
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download